Unknown

Dataset Information

0

Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.

ABSTRACT: Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.

SUBMITTER: Titanji BK 

PROVIDER: S-EPMC7337637 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Predictors of progression from moderate to severe coronavirus disease 2019: a retrospective cohort.
| S-EPMC7331556 | biostudies-literature
Unknown Open-label randomized control trial of hydroxychloroquine in patients with moderate to severe coronavirus disease 2019 infection.
| S-EPMC8313076 | biostudies-literature
Unknown Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019.
| S-EPMC8711791 | biostudies-literature
Unknown Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019.
| S-EPMC7797739 | biostudies-literature
Unknown The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea.
| S-EPMC7453989 | biostudies-literature
Unknown Holistic care for patients with severe coronavirus disease 2019: An expert consensus.
| S-EPMC7128660 | biostudies-literature
Unknown Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al.
| S-EPMC7454400 | biostudies-literature
Unknown Plasma Exchange in Patients With Severe Coronavirus Disease 2019: A Single-Center Experience.
| S-EPMC8382335 | biostudies-literature
Unknown Tocilizumab for the treatment of severe coronavirus disease 2019.
| S-EPMC7267594 | biostudies-literature
Unknown Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.
| S-EPMC7221473 | biostudies-literature